Trial Profile

A Phase 1, Randomized, Open-label, Parallel-group Study to Compare the Pharmacokinetic Properties of CSL312 Administered by Subcutaneous Prefilled Syringe Assembled to Autoinjector to Prefilled Syringe Assembled to Needle Safety Device in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Garadacimab (Primary)
Indications COVID 2019 infections; Hereditary angioedema; Idiopathic pulmonary fibrosis; Interstitial lung diseases
Focus Pharmacokinetics
Sponsors CSL Behring

26 Feb 2024 Results for safety, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
05 Oct 2022 Status changed from active not recruiting to completed.
03 Oct 2022 Status changed from recruiting to active not recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com